106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved
ESCAH1913b
Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality
patient care. It focuses on the needs of primary care practice, but also is applicable to providers
at all levels. is pocket guide should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. e ultimate judgment concerning the
propriety of any course of conduct must be made by the clinician aer consideration of each
individual patient situation. Neither IGC, the medical associations, nor the authors endorse
any product or service associated with the distributor of this clinical reference tool.
Source
Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg
HFL, Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia
Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice. J Clin
Endocrinol Metab. 2018;103:1-46.
Abbreviations
17OHP, 17-hydroxyprogesterone; 21OHD, 21-hydroxylase deficiency; CAH,
congenital adrenal hyperplasia (both classic and nonclassic); Dex, dexamethasone;
GC, glucocorticoid; LC-MS/MS, liquid chromatography-tandem mass spectrometry;
MC, mineralocorticoid; NCCAH, nonclassic congenital adrenal hyperplasia
Grading System
Strength of
Recommendation
1 = strong 2 = conditional UGPS = ungraded
good practice statement
Quality of
Evidence
⊕⊕⊕⊕
= high
⊕⊕⊕
= moderate
⊕⊕
= low
⊕
= very low
